论文部分内容阅读
目的 :观察磷微球治疗晚期肝癌的副反应并探讨其防治方法。方法 :1994年 3月至 1998年 2月 ,采用32 磷 玻璃微球 ( phosphorus 32 glassmicrospheres ,32 P GMS) 2 .6～ 17.9mCi,术中栓塞法附加肝动脉结扎及置管化疗 2 3例 (OAE +HAL) ,经Seldinger导管栓塞法 2 1例 (TAE) ,以纯甘油或碘化油作媒介加化疗药制成放化疗综合性栓塞液。结果 :全组OAE +HAL组副反应高于TAE组 ;均无骨髓抑制和肾毒性 ;肝功指标多呈一过性改变 ,4例肝功恶化 ;肺、胃肠、脾、脑、胆、胰异位栓塞各为 2、3、1、1、4、2例。 4 4例肿瘤缩小率为 4 6.7+2 4 .5% ( 0～ 91.8% ) ,9/ 2 3例癌栓缩小 ,2 5/2 7例AFP下降 ,肿瘤稳定期 5.3± 3.9月 ,平均生存 12 .5± 9.2月。结论 :61μ的32 P GMS可成为治疗肝癌安全有效的临床医用生物材料。良好的病例选择、合理的内照射剂量是有效降低术后近期并发症和提高远期疗效的关键
Objective: To observe the side effects of phosphorus microspheres in the treatment of advanced liver cancer and to explore its prevention and treatment. Methods: From March 1994 to February 1998, 32 32 microspheres (32 P GMS) were used. The mean arterial pressure was 32 ~ 60 cm / OAE + HAL), 21 cases of Seldinger catheter embolization (TAE), pure glycerol or iodized oil as a medium plus chemotherapy drugs made of radiotherapy and chemotherapy embolization. Results: All the side effects of OAE + HAL group were higher than that of TAE group. None of the patients had myelosuppression and nephrotoxicity. The liver function indexes changed transiently, 4 cases of liver function were deteriorated, lung, gastrointestinal, spleen, brain, gallbladder, Pancreatic ectopic embolism of 2,3,1,1,4,2 cases. 4 4 cases of tumor shrinkage rate of 4 6.7 +24.5% (0 ~ 91.8%), 9/2 of 3 cases of tumor emboli shrink, 2 5/2 7 cases of AFP decreased tumor stability of 5.3 ± 3. 9 months, the average survival 12.5 ± 9.2 months. Conclusion: 61μ 32 P GMS can be a safe and effective clinical medical biomaterial for the treatment of liver cancer. Good case selection, reasonable internal dose is the key to effectively reduce the postoperative short-term complications and improve long-term efficacy